COMPASS Pathways (NASDAQ:CMPS) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of COMPASS Pathways (NASDAQ:CMPS) in a report published on Friday, Benzinga reports.

Several other brokerages have also recently weighed in on CMPS. Morgan Stanley assumed coverage on shares of COMPASS Pathways in a report on Monday, April 1st. They issued an overweight rating and a $30.00 target price on the stock. HC Wainwright restated a buy rating and issued a $120.00 price objective on shares of COMPASS Pathways in a report on Monday, May 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways currently has a consensus rating of Buy and a consensus price target of $47.40.

COMPASS Pathways Stock Down 1.3 %

COMPASS Pathways stock opened at $6.24 on Friday. The firm has a market capitalization of $426.69 million, a P/E ratio of -2.63 and a beta of 2.32. The stock’s fifty day simple moving average is $7.70 and its 200-day simple moving average is $8.86. COMPASS Pathways has a twelve month low of $5.01 and a twelve month high of $12.75. The company has a current ratio of 15.23, a quick ratio of 15.23 and a debt-to-equity ratio of 0.12.

COMPASS Pathways (NASDAQ:CMPS) last issued its quarterly earnings results on Wednesday, May 8th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.52) by ($0.03). As a group, equities analysts expect that COMPASS Pathways will post -2.24 earnings per share for the current fiscal year.

Insider Buying and Selling

In other COMPASS Pathways news, major shareholder George Jay Goldsmith sold 9,621 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $8.29, for a total value of $79,758.09. Following the transaction, the insider now directly owns 3,966,052 shares in the company, valued at $32,878,571.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder George Jay Goldsmith sold 9,621 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $8.29, for a total value of $79,758.09. Following the completion of the sale, the insider now directly owns 3,966,052 shares of the company’s stock, valued at $32,878,571.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, major shareholder Ekaterina Malievskaia sold 25,750 shares of the firm’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $8.65, for a total value of $222,737.50. Following the transaction, the insider now directly owns 4,036,154 shares in the company, valued at approximately $34,912,732.10. The disclosure for this sale can be found here. Insiders sold a total of 85,002 shares of company stock worth $736,921 over the last 90 days. 4.25% of the stock is owned by insiders.

Institutional Investors Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in shares of COMPASS Pathways during the first quarter worth approximately $201,000. Tidal Investments LLC grew its position in COMPASS Pathways by 43.6% during the 1st quarter. Tidal Investments LLC now owns 19,082 shares of the company’s stock worth $159,000 after purchasing an additional 5,795 shares during the last quarter. Kennedy Capital Management LLC acquired a new position in COMPASS Pathways in the first quarter valued at $139,000. SVB Wealth LLC purchased a new stake in shares of COMPASS Pathways in the first quarter valued at about $443,000. Finally, Affinity Asset Advisors LLC boosted its stake in shares of COMPASS Pathways by 86.9% during the first quarter. Affinity Asset Advisors LLC now owns 1,027,868 shares of the company’s stock worth $8,552,000 after buying an additional 477,868 shares during the period. Hedge funds and other institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.